Beijing Tsingke Biotech Co., Ltd.
PrivateLast Round
Series B
Dec 5, 2022
Total Funding Raised
$88.71M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Beijing Tsingke Biotech Co., Ltd. operates in Healthcare & Life Sciences and is based in Beijing. Its latest recorded funding round was a Series B round in December 2022.
Beijing Tsingke Biotech Co., Ltd. is a biotechnology company that provides synthetic genomics products, life science research equipment, and biomanufacturing services for pharmaceutical, agricultural, and environmental science applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Beijing Tsingke Biotech Co., Ltd. Comparables
Compare Beijing Tsingke Biotech Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BBI Life Sciences Corporation | 88% | |
| Shanghai Generay Biotech Co., Ltd. | 84% | |
| Synbio Technologies | 82% |
For institutional investors. Book with your work email.
Beijing Tsingke Biotech Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 5, 2022 | ||||
| Series A | Jan 28, 2022 | ||||
| Angel | May 1, 2021 |
For institutional investors. Book with your work email.
Beijing Tsingke Biotech Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Beijing E-Town International Investment & Development Co., Ltd. | Angel |
| Shenzhen Dachen Caizhi Venture Capital Management | Series B |
| Cowin Capital | Angel |
| SB China Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 141% MoM, from 1.5K to 3.6K.
- Apr 16, 2026
Monthly visitors increased 77% MoM, reaching 4.6K.
For institutional investors. Book with your work email.
Beijing Tsingke Biotech Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Beijing Tsingke Biotech Co., Ltd.'s valuation, stock price, and market status.
Is Beijing Tsingke Biotech Co., Ltd. a public or private company?
Beijing Tsingke Biotech Co., Ltd. is a private company.
What is the current stock price of Beijing Tsingke Biotech Co., Ltd.?
Beijing Tsingke Biotech Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Beijing Tsingke Biotech Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Beijing Tsingke Biotech Co., Ltd. worth (valuation)?
Valuation information for Beijing Tsingke Biotech Co., Ltd. is not publicly available.
Can I buy Beijing Tsingke Biotech Co., Ltd. stock?
Beijing Tsingke Biotech Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Beijing Tsingke Biotech Co., Ltd.'s last funding round?
Beijing Tsingke Biotech Co., Ltd.'s most recent funding round was Series B on December 5, 2022.
Who are the main investors in Beijing Tsingke Biotech Co., Ltd.?
Key investors in Beijing Tsingke Biotech Co., Ltd. include Shenzhen Dachen Caizhi Venture Capital Management.
Will Beijing Tsingke Biotech Co., Ltd. IPO soon?
No public IPO plans have been announced for Beijing Tsingke Biotech Co., Ltd..
How can I track Beijing Tsingke Biotech Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Beijing Tsingke Biotech Co., Ltd.'s shares on secondary markets.